The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease

British Journal of Clinical Pharmacology

Volumn 47, Issue 2, 1999, Pages 219-222

  Taylor, A ^a   Beerahee, A ^a   Citerone, D ^a   Davy, M ^a   Fitzpatrick, K ^a   Lopez Gil, A ^a   Stocchi, F ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Digoxin; Parkinson's disease; Pharmacokinetics; Ropinirole

Indexed keywords

ANTIPARKINSON AGENT; CARDIAC GLYCOSIDE; DIGOXIN; ROPINIROLE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

AGED; ANTI-ARRHYTHMIA AGENTS; ANTIPARKINSON AGENTS; DIGOXIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; INDOLES; PARKINSON DISEASE; PLACEBOS; SINGLE-BLIND METHOD;

EID: 0033050896     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00867.x     Document Type: Article

References (9)

1. 2 agonist. Pharmacol Biochem Behav 1991; 38: 147-154.
2. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F, on behalf of the 056 Study Group. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year L-dopa-controlled study. Mov Disord 1998; 13: 39-45.
3. Beerahee A, Taylor AC, Citerone D, et al. Steady-state pharmacokinetics of digoxin during repeat oral administration of ropinirole in parkinsonian patients. Br J Clin Pharmacol 1996; 42: 668-669P.
4. Nation RL, Sansom LN. Bioequivalence requirements for generic products. Pharmacol Ther 1994; 62: 41-55.
5. Brown DD, Juhl RP, Warner SL. Decreased bioavailability of digoxin due to hypocholesterolemic interventions. Circulation 1978; 58: 164-172.
6. Kirch W, Janisch HD, Santos SR, Duhrsen U, Dylewicz P, Ohnhaus EE. Effect of cisapride and metoclopramide on digoxin bioavailability. Eur J Drug Metab Pharmacokinet 1986; 11: 249-250.
7. Redfors A. Plasma digoxin concentration - its relation to digoxin dosage and clinical effects in patients with atrial fibrillation. Br Heart J 1972; 34: 383-391.
8. Cauffield JS, Gums JG, Grauer K. The serum digoxin concentration: ten questions to ask. Am Family Physician 1997; 56: 495-503.
9. Dobbs RJ, O'Neill CJA, Deshmukh AA, Nicholson PW, Dobbs SM. Serum concentration monitoring of cardiac glycosides. Clin Pharmacokinet 1991; 20: 175-193.